Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis

被引:351
作者
Qiu, Min [1 ,5 ]
Tang, Yan [2 ,3 ]
Chen, Jinjin [1 ]
Muriph, Rachel [4 ]
Ye, Zhongfeng [1 ]
Huang, Changfeng [1 ]
Evans, Jason [4 ]
Henske, Elizabeth P. [2 ,3 ]
Xu, Qiaobing [1 ]
机构
[1] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA
[2] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Univ Massachusetts, Dept Chem, Boston, MA 02125 USA
[5] Fudan Univ, Phenome Inst, Shanghai 201203, Peoples R China
关键词
lipid nanoparticles; lung-targeted delivery; lymphangioleiomyomatosis; tuberous sclerosis complex; mRNA; CO-DELIVERY; IN-VIVO; SIROLIMUS; EFFICACY; VACCINES; SAFETY; CELLS;
D O I
10.1073/pnas.2116271119
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Safe and efficacious systemic delivery of messenger RNA (mRNA) to specific organs and cells in vivo remains the major challenge in the development of mRNA-based therapeutics. Targeting of systemically administered lipid nanoparticles (LNPs) coformulated with mRNA has largely been confined to the liver and spleen. Using a library screening approach, we identified that N-series LNPs (containing an amide bond in the tail) are capable of selectively delivering mRNA to the mouse lung, in contrast to our previous discovery that O-series LNPs (containing an ester bond in the tail) that tend to deliver mRNA to the liver. We analyzed the protein corona on the liver- and lung-targeted LNPs using liquid chromatography-mass spectrometry and identified a group of unique plasma proteins specifically absorbed onto the surface that may contribute to the targetability of these LNPs. Different pulmonary cell types can also be targeted by simply tuning the headgroup structure of N-series LNPs. Importantly, we demonstrate here the success of LNP-based RNA therapy in a preclinical model of lymphangioleiomyomatosis (LAM), a destructive lung disease caused by loss-of-function mutations in the Tsc2 gene. Our lungtargeting LNP exhibited highly efficient delivery of the mouse tuberous sclerosis complex 2 (Tsc2) mRNA for the restoration of TSC2 tumor suppressor in tumor and achieved remarkable therapeutic effect in reducing tumor burden. This research establishes mRNA LNPs as a promising therapeutic intervention for the treatment of LAM.
引用
收藏
页数:10
相关论文
共 52 条
[1]   mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials [J].
A Feldman, Robert ;
Fuhr, Rainard ;
Smolenov, Igor ;
Ribeiro, Amilcar ;
Panther, Lori ;
Watson, Mike ;
Senn, Joseph J. ;
Smith, Mike ;
Almarsson, Orn ;
Pujar, Hari S. ;
Laska, Michael E. ;
Thompson, James ;
Zaks, Tal ;
Ciaramella, Giuseppe .
VACCINE, 2019, 37 (25) :3326-3334
[2]   Cystic fibrosis airway epithelium remodelling: involvement of inflammation [J].
Adam, Damien ;
Roux-Delrieu, Jacqueline ;
Luczka, Emilie ;
Bonnomet, Arnaud ;
Lesage, Julien ;
Merol, Jean-Claude ;
Polette, Myriam ;
Abely, Michel ;
Coraux, Christelle .
JOURNAL OF PATHOLOGY, 2015, 235 (03) :408-419
[3]   The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs [J].
Akinc, Akin ;
Maier, Martin A. ;
Manoharan, Muthiah ;
Fitzgerald, Kevin ;
Jayaraman, Muthusamy ;
Barros, Scott ;
Ansell, Steven ;
Du, Xinyao ;
Hope, Michael J. ;
Madden, Thomas D. ;
Mui, Barbara L. ;
Semple, Sean C. ;
Tam, Ying K. ;
Ciufolini, Marco ;
Witzigmann, Dominik ;
Kulkarni, Jayesh A. ;
van der Meel, Roy ;
Cullis, Pieter R. .
NATURE NANOTECHNOLOGY, 2019, 14 (12) :1084-1087
[4]   Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA [J].
Ball, Rebecca L. ;
Hajj, Khalid A. ;
Vizelman, Jamie ;
Bajaj, Palak ;
Whitehead, Kathryn A. .
NANO LETTERS, 2018, 18 (06) :3814-3822
[5]   Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics [J].
Bhaoighill, Muireann Ni ;
Dunlop, Elaine A. .
CANCER DRUG RESISTANCE, 2019, 2 (04) :1069-1085
[6]   Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis [J].
Bissler, John J. ;
McCormack, Francis X. ;
Young, Lisa R. ;
Elwing, Jean M. ;
Chuck, Gail ;
Leonard, Jennifer M. ;
Schmithorst, Vincent J. ;
Laor, Tal ;
Brody, Alan S. ;
Bean, Judy ;
Salisbury, Shelia ;
Franz, David N. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (02) :140-151
[7]   The Crown and the Scepter: Roles of the Protein Corona in Nanomedicine [J].
Cai, Rong ;
Chen, Chunying .
ADVANCED MATERIALS, 2019, 31 (45)
[8]   Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing [J].
Cheng, Qiang ;
Wei, Tuo ;
Farbiak, Lukas ;
Johnson, Lindsay T. ;
Dilliard, Sean A. ;
Siegwart, Daniel J. .
NATURE NANOTECHNOLOGY, 2020, 15 (04) :313-+
[9]   Dendrimer-Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I [J].
Cheng, Qiang ;
Wei, Tuo ;
Jia, Yuemeng ;
Farbiak, Lukas ;
Zhou, Kejin ;
Zhang, Shuyuan ;
Wei, Yonglong ;
Zhu, Hao ;
Siegwart, Daniel J. .
ADVANCED MATERIALS, 2018, 30 (52)
[10]   Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system [J].
DeRosa, F. ;
Guild, B. ;
Karve, S. ;
Smith, L. ;
Love, K. ;
Dorkin, J. R. ;
Kauffman, K. J. ;
Zhang, J. ;
Yahalom, B. ;
Anderson, D. G. ;
Heartlein, M. W. .
GENE THERAPY, 2016, 23 (10) :699-707